




July 2011

Volume 16 · Numbers 13/14

pp. 541–642



Cover Story

The leading story of this issue of *Drug Discovery Today*, by Marie-Luce De Temmerman, Joanna Rejman, Jo Demeester, Darrell J. Irvine, Bruno Gander and Stefaan C. De Smedt discusses the rationale for the use of particulate vaccines. The authors provide an overview of the particulate antigen delivery systems being developed and those currently in use. The article elaborates on the strategic use of particulate antigen delivery systems.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

555 A molecular informatics view on best practice in multi-parameter compound optimization

Scott J. Lusher, Ross McGuire, Rita Azevedo, Jan-Willem Boiten, Rene C. van Schaik and Jacob de Vlieg

569 Particulate vaccines: on the quest for optimal delivery and immune response

Marie-Luce De Temmerman, Joanna Rejman, Jo Demeester, Darrell J. Irvine, Bruno Gander and Stefaan C. De Smedt

583 A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements

Adam J. Schwarz, Lino Becerra, Jaymin Upadhyay, Julie Anderson, Richard Baumgartner, Alexandre Coimbra, Jeff Evelhoch, Richard Hargreaves, Brigitte Robertson, Smriti Iyengar, Johannes Tauscher, David Bleakman and David Borsook

INFORMATICS

594 Electronic health records: Implications for drug discovery

Lixia Yao, Yiye Zhang, Yong Li, Philippe Sanseau and Pankaj Agarwal

POST SCREEN

600 A generic operational strategy to qualify translational safety biomarkers

Katja Matheis, David Laurie, Christiane Andriamandroso, Nadir Arber, Lina Badimon, Xavier Benain, Kaidre Bendjama, Isabelle Clavier, Peter Colman, Hüseyin Firat, Jens Goepfert, Steve Hall, Thomas Joos, Sarah Kraus, Axel Kretschmer, Michael Merz, Teresa Padro, Hannes Planatscher, Annamaria Rossi, Nicole Schneiderhan-Marra, Ina Schuppe-Koistinen, Peter Thomann, Jean-Marc Vidal and Béatrice Molac

609 Portfolio management in early stage drug discovery – a traveler's guide through uncharted territory

Ulrich A.K. Betz

619 PLK1 as an oncology target: current status and future potential

Campbell McInnes and Michael D. Wyatt

626 The impact of epigenomics on future drug design and new therapies

Christopher A. Hamm and Fabricio F. Costa

636 Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering

Jens Schamberger, Michael Grimm, Andreas Steinmeyer and Alexander Hillisch